Stuart Chaussee & Associates’s AstraZeneca AZN Stock Holding History

Stuart Chaussee & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-83	Closed	-$12.7K	–	16
2025 Q3	$12.7K	Hold	83	–	–	﹤0.01%	144
2025 Q2	$11.5K	Hold	83	–	–	﹤0.01%	144
2025 Q1	$12.1K	Hold	83	–	–	﹤0.01%	143
2024 Q4	$10.8K	Hold	83	–	–	﹤0.01%	143
2024 Q3	$12.9K	Hold	83	–	–	﹤0.01%	124
2024 Q2	$12.9K	Hold	83	–	–	﹤0.01%	119
2024 Q1	$11.2K	Hold	83	–	–	﹤0.01%	123
2023 Q4	$11.1K	Hold	83	–	–	﹤0.01%	113
2023 Q3	$11.2K	Hold	83	–	–	﹤0.01%	88
2023 Q2	$11.8K	Hold	83	–	–	﹤0.01%	85
2023 Q1	$11.5K	Hold	83	–	–	﹤0.01%	81
2022 Q4	$11.2K	Hold	83	–	–	﹤0.01%	94
2022 Q3	$9K	Hold	83	–	–	0.02%	93
2022 Q2	$11K	Hold	83	–	–	0.02%	93
2022 Q1	$11K	Hold	83	–	–	0.01%	108
2021 Q4	$10K	Hold	83	–	–	﹤0.01%	119
2021 Q3	$10K	Hold	83	–	–	0.02%	97
2021 Q2	$10K	Hold	83	–	–	﹤0.01%	104
2021 Q1	$8K	Buy	+83	New	+$8.34K	﹤0.01%	134

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stuart Chaussee & Associates's AZN Position: Q4 2025 in Review

Stuart Chaussee & Associates sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 83 shares — an estimated $12.7K sold.

Stuart Chaussee & Associates first reported a position in AZN in Q1 2021 and held it in 19 quarters. The position peaked at $12.9K in Q2 2024. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Stuart Chaussee & Associates reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Stuart Chaussee & Associates sold 83 AstraZeneca shares in Q4 2025, an estimated $12.7K.
Stuart Chaussee & Associates first reported a position in AstraZeneca in Q1 2021 and held it in 19 quarters.
Stuart Chaussee & Associates's AstraZeneca position peaked at $12.9K in Q2 2024.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Stuart Chaussee & Associates's 13F filing for Q4 2025.